Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...
The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain. While symptoms can now be better managed with lifelong treatment, there is ...
Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...
On the left is integrase in its “intasome” structure of four identical four-part complexes (pink) that connect to create one 16-part complex that locks around viral DNA (blue). On the right is ...
In a groundbreaking discovery, researchers from Florida Atlantic University's Charles E. Schmidt College of Medicine have identified a never-before-seen mechanism that enables the human ...
In individuals who started antiretroviral therapy during acute HIV infection, the proliferative capacity of HIV-specific CD8+ T-cells at 24 weeks of therapy predicted the subsequent reduction in the ...
On the left is integrase in its “intasome” structure of four identical four-part complexes (pink) that connect to create one 16-part complex that locks around viral DNA (blue). On the right is ...
Over the past three decades, there have been amazing advances in treating and preventing HIV. It's now a manageable infection. A person with HIV who takes HIV medicine consistently, before their ...
Children born with HIV and treated early with antiretroviral therapy (ART) continued to show elevated immune markers in adolescence, based on data presented at the International AIDS Society ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results